Introduction {#s1}
============

Chronic kidney disease (CKD) is defined as the presence of kidney damage or a decreased glomerular filtration rate (GFR) of less than 60 ml/min/1.73 m^2^ for at least 3 months ([@B44]). Progression of CKD to end-stage renal disease (ESRD) requires renal replacement therapy (RRT) for survival. Although recent decades have seen great advances in the understanding of disease pathophysiology, CKD continues to be a global concern with an estimated global prevalence of 10--15%. In Europe, about 70 million people are affected with CKD, and the prevalence of RRT has grown by almost 50% over the past decade ([@B41]).

It is generally accepted that inflammation is an essential part of CKD. In the Chronic Renal Insufficiency Cohort (CRIC) study, biomarkers of inflammation were inversely associated with measures of kidney function and positively with albuminuria in CKD patients ([@B11]). An excess of proinflammatory cytokines or insufficient anti-inflammatory cytokines production may play a role in the development of CKD. Over the past decade, there has been a growing interest in the association between CKD and anti-inflammatory cytokines including transforming growth factor-β1 (TGF-β1), interleukin-4 (IL-4), and IL-10.

TGF-β1 is well known for its contribution to renal inflammation and fibrosis. The overexpression of TGF-β1 decreases the accumulation of macrophages and T cells and reduces inflammatory mediator release in CKD mice ([@B14]). Kidney tissue progressive fibrosis and subsequent sclerosis is a common pathological phenomenon characteristic for ESRD. TGF-β1 exerts its profibrotic activity through stimulation of fibroblast proliferation, extracellular matrix synthesis, and epithelial-to-mesenchymal transition (EMT). IL-4 is a multifunctional cytokine that plays a critical role in the control and regulation of the immune and inflammatory system. Increased IL-4 production is associated with attenuated inflammation in CKD rats ([@B37]). In addition, adoptive transfer of IL-4-induced M2 macrophages significantly reduces histological and functional injury in a mouse model of chronic inflammatory renal disease ([@B43]). As an important immunoregulatory cytokine, IL-10 suppresses inflammatory mediator release and has been shown to ameliorate inflammation in animal models of CKD ([@B30]). The inhibition of IL-10 decreases renal function and is associated with worsening of histological features in experimental renal disease ([@B38]).

Given the important role these cytokines play in the development of CKD, we sought to evaluate the relationship between common genetic polymorphisms within these cytokine genes and susceptibility to CKD using a meta-analysis study design.

Methods {#s2}
=======

Search Strategy {#s2_1}
---------------

This meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline ([@B29]). The search strategy in this meta-analysis was originally established to find studies examining the association of polymorphisms in the *TGF-β1*, *IL-4*, and *IL-10* genes with CKD susceptibility. A literature search was performed within five scientific databases (PubMed, Medline, Embase, Web of Science, and China National Knowledge Infrastructure) from inception until October 2019. The following keywords were used in combination: transforming growth factor-β1, interleukin-4, interleukin-10, TGF-β1, IL-4, IL-10, chronic kidney disease, chronic renal failure, end-stage renal disease, polymorphism, and variant. After removing duplicates, two reviewers (MM and YJ) independently reviewed the titles and abstracts. Relevant studies were selected and underwent a full text review. Discrepancies between the two reviewers were resolved by discussion and consensus. When institutions published duplicate studies with accumulating numbers of CKD patients, only the most complete studies were included in the final analysis. The electronic search was supplemented by a hand-search of reference lists from the selected publications and relevant meta-analyses.

Inclusion Criteria {#s2_2}
------------------

CKD was defined as decreased kidney function shown by glomerular filtration rate (GFR) of less than 60 ml/min per 1.73 m^2^, or markers of kidney damage, or both, of at least 3 months duration, regardless of the underlying cause ([@B44]). We included studies that fulfilled the following inclusion criteria: 1) studies assessed the association between the *TGF-β1*, *IL-4*, and *IL-10* polymorphisms and CKD susceptibility, 2) case-control studies with human subjects, 3) for case-control study, cases were CKD patients, whereas comparators (controls) were subjects without CKD; 4) standard methods used for genotyping, and 5) summary odds ratios (ORs) and 95% confidence intervals (CIs) were used to evaluate the susceptibility to CKD. We excluded case-only studies, conference papers, abstracts, meta-analyses, reviews, and studies that had no sufficient data.

Data Extraction and Quality Assessment {#s2_3}
--------------------------------------

Two reviewers (MM and YJ) independently performed data extraction. Data were extracted from texts or tables as required. The following data were recorded for each report including publication details (i.e., name of the first author, country, ethnicity, and year of publication), characteristics of study subjects (age, gender and sample size, source of controls), genotypes, and methods used for genotyping. Quality assessment of the included studies was based on the Newcastle Ottawa Scale (NOS) for case-control studies.

Statistical Analysis {#s2_4}
--------------------

Quantitative syntheses and meta-analyses were produced using the statistical software Stata 12.0 (Texas, USA). The strength of association between polymorphisms in the *TGF-β1*, *IL-4*, and *IL-10* polymorphisms and CKD susceptibility was assessed using ORs and 95% CIs under dominant, recessive, and homozygote genetic models. The Z-test was applied to determine the significance of the pooled OR; P-value less than 0.05 was considered statistically significant. Between-study heterogeneity was evaluated by calculating the Q-value and I^2^ statistic that quantified the proportion variation that is owing to heterogeneity rather than chance ([@B12]). The fixed effects model was applied to pool the data when I^2^ \< 50% or P \> 0.10, otherwise the random effects model was used. Publication bias for each comparison was assessed by examining asymmetry funnel plots and using Egger\'s test. Sensitivity analyses were performed by excluding a single study at a time to evaluate the consistency of the results.

Results {#s3}
=======

Study Characteristics {#s3_1}
---------------------

A detailed flow diagram of study selection is shown in [**Figure 1**](#f1){ref-type="fig"}. Our literature search identified 451 records. After removing duplicates, the title and abstract of the remaining 262 articles were screened and 234 records were excluded. For 28 potentially relevant studies, full-text was retrieved and evaluated for eligibility. Ultimately a total of 19 studies from 10 different countries satisfied our inclusion criteria. Of these studies, 10 studies evaluated the *TGF-β1* polymorphisms (rs1800469, rs1800471, and rs1800470) ([@B20]; [@B17]; [@B2]; [@B40]; [@B26]; [@B33]; [@B8]; [@B31]; [@B7]; [@B16]), 3 studies investigated the *IL-4* rs8179190 polymorphism ([@B27]; [@B42]; [@B19]), and 8 studies assessed the *IL-10* polymorphisms (rs1800896 and rs1800871) ([@B45]; [@B2]; [@B23]; [@B5]; [@B4]; [@B32]; [@B36]; [@B16]). The included studies were done in Europe and Asia. Year of recruitment varied from 2004 to 2019. All studies included in the final analysis recruited patients with CKD and non-CKD controls. [**Table 1**](#T1){ref-type="table"} summarizes the characteristics of the included studies. The details of quality assessment is shown in [**Supplementary Table 1**](#SM1){ref-type="supplementary-material"}.

![Flow diagram of study selection and inclusions.](fgene-11-00079-g001){#f1}

###### 

Characteristics of the included case-control studies.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author            Year   Country       Ethnicity   Sample size (n)   Cases' characteristics   Controls\' characteristics                                                       Age                                                                 Female gender (%)   Variants           NOS   Genotyping method                                            
  ----------------- ------ ------------- ----------- ----------------- ------------------------ -------------------------------------------------------------------------------- ------------------------------------------------------------------- ------------------- ------------------ ----- ------------------- ------------------------------------ --- ----------------------------------
  ***TGF-β1***                                                                                                                                                                                                                                                                                                                                                 

  Lee-Chen          2004   China         Asian       14                170                      ESRD                                                                             University students with normal renal sonogram\                     1--10 years         NR                 NR    NR                  rs1800469                            7   PCR-RFLP
                                                                                                                                                                                 and without pyuria                                                                                                                                                            

  Khalil            2005   UK            Caucasian   145               100                      CKD patients with various degrees of renal insufficiency                         Caucasian control subjects of Northern European origin              19--80 years        19--80 years old   NR    NR                  rs1800469, rs1800471 and rs1800470   8   PCR

  Babel             2006   Germany       Caucasian   103               118                      CKD patients                                                                     Healthy blood donors                                                NR                  41 ± 8.4           38    57                  rs1800470 and rs1800471              8   PCR-SSP

  van de Wetering   2006   Netherlands   Caucasian   57                180                      ESRD                                                                             Heart transplant recipients without CKD                             15--64 years        4--71 years old    12    22                  rs1800470 and rs1800471              7   PCR

  Mittal            2007   India         Asian       172               180                      ESRD                                                                             Healthy controls                                                    38 ± 11.2           39 ± 12.4          17    36                  rs1800470 and rs1800471              7   ARMS-PCR

  Prasad            2007   India         Asian       196               225                      CKD patients                                                                     Diabetics without any evidence of diabetic kidney disease           57 ± 12.8           61 ± 11.5          67    66                  rs1800469                            6   PCR-RFLP

  Dong              2011   China         Asian       58                70                       CKD patients with various degrees of renal insufficiency                         Healthy controls                                                    NR                  38 ± 9.6           NR    44                  rs1800470                            7   PCR-SSP

  Nabrdalik         2013   Poland        Caucasian   109               111                      CKD patients                                                                     Old people without any signs of CKD                                 25 ± 12.9           93 ± 3.1           42    63                  rs1800471                            8   PCR-RFLP

  Cuenca            2014   Spain         Caucasian   84                80                       Patients with CKD at the 6th month after liver transplantation                   Patients without CKD at the 6th month after liver transplantation   53 ± 9.8            45 ± 11.9          42    31                  rs1800470 and rs1800471              8   PCR-SSOP

  Kamei             2016   Japan         Asian       16                46                       Patients with CKD at median follow-up of 9.2 years after liver transplantation   Patients without CKD after liver transplantation                    57 ± 4.9            48 ± 11.2          38    39                  rs1800470                            8   PCR-CTPP

  ***IL-10***                                                                                                                                                                                                                                                                                                                                                  

  Wu                2005   China         Asian       870               1,000                    ESRD patients                                                                    Healthy controls                                                    54 ± 15             52 ± 13            50    50                  rs1800896                            6   PCR-RFLP

  Babel             2006   Germany       Caucasian   103               114                      Adult CKD patients                                                               Healthy blood donors                                                NR                  41 ± 8.4           38    57                  rs1800896                            8   PCR-SSP

  Manchanda         2009   India         Asian       184               180                      ESRD patients                                                                    Healthy controls                                                    35 ± 8.6            NR                 13    NR                  rs1800896 and rs1800871              7   PCR

  Buckham           2010   UK            Caucasian   664               577                      Patients with ESRD                                                               Donors who did not have kidney disease                              42 ± 16.7           37 ± 16.8          38    41                  rs1800896 and rs1800871              7   PCR

  Bloudíčková       2011   Czech         Caucasian   492               500                      Patients with ESRD                                                               Subjects without renal disorder                                     65 ± 13.1           NR                 NR    NR                  rs1800896                            8   PCR-RFLP

  Okada             2012   Japan         Asian       546               2767                     Adult CKD patients                                                               Non-CKD controls                                                    61 ± 7.2            56 ± 8.7           54    51                  rs1800871                            7   Multiple PCR-based invader assay

  Sharma            2013   India         Asian       257               200                      ESRD patients                                                                    Healthy controls                                                    NR                  NR                 22    26                  rs1800896 and rs1800871              8   PCR

  Kamei             2016   Japan         Asian       16                46                       Patients with CKD at median follow-up of 9.2 years after liver transplantation   Patients without CKD after liver transplantation                    57 ± 4.9            48 ± 11.2          38    39                  rs1800871                            7   PCR-CTPP

  ***IL-4***                                                                                                                                                                                                                                                                                                                                                   

  Mittal            2007   India         Asian       193               180                      ESRD patients                                                                    Healthy controls                                                    35 ± 8.6            35 ± 11.3          11    43                  rs8179190                            7   PCR

  Vasudevan         2011   Malaysia      Asian       160               160                      ESRD patients                                                                    Healthy controls                                                    25--86 years        25--86 years       NR    NR                  rs8179190                            7   PCR

  Ksiazek           2019   Poland        Caucasian   262               180                      ESRD patients                                                                    Healthy controls                                                    23--93 years        28--88 years       48    50                  rs8179190                            8   PCR
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ESRD, end-stage renal disease; CKD, chronic kidney disease; NR, not reported; PCR, polymerase chain reaction; PCR-CTPP, polymerase chain reaction with confronting two-pair primers; PCR-RFLP, polymerase chain reaction restriction fragment length polymorphism; PCR-SSP, polymerase chain reaction-sequence specific primer; PCR-SSOP, polymerase chain reaction-sequence-specific oligonucleotide probing.

Data Synthesis {#s3_2}
--------------

Seven studies including 614 cases and 747 controls evaluated *TGF-β1* rs1800470 and its association with susceptibility to CKD ([@B17]; [@B2]; [@B40]; [@B26]; [@B8]; [@B7]; [@B16]). The results of the overall meta-analysis did not suggest any association between rs1800470 and CKD susceptibility for all genetic models (CC + TC *vs*. TT, OR = 1.39, 95% CI: 0.57--3.39, P = 0.470; CC *vs*. CT + TT, OR = 1.37, 95% CI: 0.74--2.56, P = 0.319; CC *vs*. TT, OR = 1.86, 95% CI: 0.55--6.25, P = 0.317) ([**Table 2**](#T2){ref-type="table"} and [**Figure 2A**](#f2){ref-type="fig"}). We observed significant heterogeneity (I^2^ \> 50%). In the stratified analysis based on ethnicity, we found that rs1800470 was associated with increased susceptibility to CKD in Asians (CC + TC *vs*. TT, OR = 2.90, 95% CI: 1.90--4.44, P = 0.000; CC *vs*. CT + TT, OR = 2.28, 95% CI: 1.50--3.46, P = 0.000; CC *vs*. TT, OR = 4.54, 95% CI: 2.57--8.00, P = 0.000) ([**Table 2**](#T2){ref-type="table"} and [**Figure 2A**](#f2){ref-type="fig"}), but not in Caucasians. The results of Egger\'s test suggested no evidence of publication bias (CC + TC *vs*. TT, P = 0.969; CC *vs*. TC + TT, P = 0.567; CC *vs*. TT, P = 0.810).

###### 

The results of meta-analysis.

  Marker               No. of studies   Dominant               Recessive   Homozygote                                                                                                       
  -------------------- ---------------- ---------------------- ----------- ------------ ------- ---------------------- ----------- ------ ------- ---------------------- ----------- ------ --------
  *TGF-β1* rs1800470                                                                                                                                                                        
   All                 7                1.39 (0.57-3.39)       0.470       90.5         0.000   1.37 (0.74-2.56)       0.319       71.1   0.004   1.86 (0.55-6.25)       0.317       88.9   0.000
   Asians              3                **2.90 (1.90-4.44)**   **0.000**   0            0.863   **2.28 (1.50-3.46)**   **0.000**   45.8   0.158   **4.54 (2.57-8.00)**   **0.000**   5.9    0.346
  Caucasians           4                0.88 (0.24-3.21)       0.852       93.1         0.000   0.98 (0.47-2.05)       0.960       59.7   0.084   1.06 (0.16-7.22)       0.927       91.7   0.000
  *TGF-β1* rs1800471                                                                                                                                                                        
   All                 6                1.28 (0.99-1.65)       0.062       36.7         0.162   **1.68 (1.02-2.77)**   **0.041**   0      0.589   **1.72 (1.03-2.85)**   **0.037**   0      0.634
   Caucasians          5                **1.42 (1.03-1.96)**   **0.035**   40.4         0.152   1.55 (0.63-3.81)       0.337       0      0.446   1.67 (0.67-4.13)       0.268       0      0.472
  Asians               1                1.07 (0.71-1.62)       0.749       NA           NA      1.74 (0.96-3.18)       0.070       NA     NA      1.74 (0.94-3.21)       0.078       NA     NA
  *TGF-β1* rs1800469                                                                                                                                                                        
   All                 3                **0.33 (0.15-0.76)**   **0.009**   49.4         0.139   0.71 (0.47-1.07)       0.099       0      0.734   **0.33 (0.15-0.73)**   **0.006**   0      0.746
   Asians              2                **0.23 (0.06-0.84)**   **0.026**   52.9         0.145   0.74 (0.48-1.13)       0.163       0      0.560   **0.31 (0.11-0.86)**   **0.025**   0      0.461
   Caucasians          1                **0.50 (0.26-0.93)**   **0.028**   NA           NA      0.53 (0.16-1.74)       0.295       NA     NA      0.39 (0.11-1.34)       0.134       NA     NA
  *IL-4* rs8179190                                                                                                                                                                          
   All                 3                0.69 (0.31-1.55)       0.370       88.9         0.000   1.68 (0.58-4.83)       0.340       70.5   0.034   1.45 (0.32-6.59)       0.633       82.4   0.003
   Asians              2                **0.48 (0.34-0.68)**   **0.000**   0            0.498   2.33 (0.21-26.23)      0.494       81.5   0.020   1.44 (0.09-24.33)      0.800       85.3   0.009
  Caucasians           1                1.47 (1.00-2.17)       0.052       NA           NA      1.76 (0.67-4.63)       0.251       NA     NA      2.01 (0.76-5.35)       0.162       NA     NA
  *IL-10* rs1800896                                                                                                                                                                         
   All                 6                0.99 (0.69-1.42)       0.959       82.2         0.000   1.10 (0.81-1.49)       0.536       78.6   0.000   1.11 (0.70-1.75)       0.665       83.6   0.0000
   Caucasians          3                0.79 (0.53-1.18)       0.249       76.3         0.015   0.99 (0.81-1.20)       0.881       0      0.429   0.87 (0.62-1.22)       0.420       46.9   0.152
   Asians              3                1.30 (0.77-2.21)       0.324       75.9         0.016   1.33 (0.70-2.52)       0.384       89.6   0.000   1.50 (0.65-3.49)       0.345       87.1   0.000
  *IL-10* rs1800871                                                                                                                                                                         
   All                 5                0.82 (0.56-1.20)       0.308       74.1         0.004   1.08 (0.93-1.26)       0.327       0      0.656   0.85 (0.52-1.40)       0.523       70.1   0.009
   Asians              4                0.73 (0.40-1.36)       0.326       80.4         0.002   1.08 (0.92-1.27)       0.322       0      0.494   0.78 (0.38-1.57)       0.479       77.5   0.004
   Caucasians          1                0.92 (0.73-1.17)       0.499       NA           NA      1.03 (0.64-1.66)       0.900       NA     NA      1.00 (0.61-1.62)       0.993       NA     NA

CI, confidence interval; NA, not applicable; OR, odds ratio. Significant results are highlighted in bold.

![Effect size and confidence intervals for studies evaluating the *TGF-β1* rs1800470, rs1800471, and rs1800469 polymorphisms. **(A)** Association between rs1800470 and chronic kidney disease susceptibility under dominant model (CC + TC *vs*. TT) using random-effects meta-analysis. **(B)** Association between rs1800471 and chronic kidney disease susceptibility under dominant model (CC + GC *vs*. GG) using fixed-effects meta-analysis. **(C)** Association between rs1800469 and chronic kidney disease susceptibility under dominant model (CC + TC vs. TT) using random-effects meta-analysis.](fgene-11-00079-g002){#f2}

Six studies with 714 CKD patients and 743 controls evaluated the relationship of *TGF-β1* rs1800471 with susceptibility to CKD ([@B17]; [@B2]; [@B40]; [@B26]; [@B31]; [@B7]). The overall OR showed a statistically significant association between this polymorphism and CKD susceptibility in the overall population under recessive and homozygote models (CC *vs*. GC + GG, OR = 1.68, 95% CI: 1.02-2.77, P = 0.041; CC *vs*. GG, OR = 1.72, 95% CI: 1.03--2.85, P = 0.037) and in Caucasians under dominant model (CC + GC *vs*. GG, OR = 1.42, 95% CI: 1.03--1.96, P = 0.035) ([**Table 2**](#T2){ref-type="table"} and [**Figure 2B**](#f2){ref-type="fig"}). There was no association with CKD susceptibility in Asians. We did not observe significant between-study heterogeneity. We did not find any evidence of publication bias using Egger\'s test (CC + GC *vs*. GG, P = 0.326; CC *vs*. GC + GG, P = 0.845; CC *vs*. GG, P = 0.759).

The association between the *TGF-β1* rs1800469 polymorphism and susceptibility to CKD was evaluated in 3 studies (251 cases and 280 controls). There was an association between rs1800469 and susceptibility to CKD in dominant (CC + TC *vs*. TT, OR = 0.33, 95% CI: 0.15--0.76, P = 0.009) and homozygote (CC *vs*. TT, OR = 0.33, 95% CI: 0.15--0.73, P = 0.006) models ([**Table 2**](#T2){ref-type="table"} and [**Figure 2C**](#f2){ref-type="fig"}). Heterogeneity was found under dominant model (I^2^ = 49.4%). When stratifying the results of meta-analysis by ethnicity, we found that rs1800469 was associated with CKD susceptibility in Asians (CC + TC *vs*. TT, OR = 0.23, 95% CI: 0.06--0.84, P = 0.026; CC *vs*. TT, OR = 0.31, 95% CI: 0.11--0.86, P = 0.025) and Caucasians (CC + TC *vs*. TT, OR = 0.50, 95% CI: 0.26--0.93, P = 0.028) ([**Table 2**](#T2){ref-type="table"}), respectively. There was no evidence for publication bias in the contrasts examined (CC + TC *vs*. TT, P = 0.462; CC *vs*. TC + TT, P = 0.082; CC *vs*. TT, P = 0.196).

Three studies assessed the *IL-4* rs8179190 polymorphism and its relationship with CKD susceptibility ([@B27]; [@B42]; [@B19]). The meta-analyses indicated a significant association between rs8179190 and CKD susceptibility in Asians under dominant model (B1B1 + B1B2 *vs*. B2B2, OR = 0.48, 95% CI: 0.34--0.68, P = 0.000) but not recessive and homozygote models (B1B1 *vs*. B1B2 + B2B2, OR = 2.33, 95% CI: 0.21--26.23, P = 0.494; B1B1 *vs*. B2B2, OR=1.44, 95% CI: 0.09--24.33, P = 0.800) ([**Table 2**](#T2){ref-type="table"} and [**Figure 3**](#f3){ref-type="fig"}). We did not find heterogeneity among Asian studies (I^2^ = 0). There was no association of rs8179190 with susceptibility to CKD in Caucasians. No publication bias was observed (B1B1 + B1B2 *vs*. B2B2, P = 0.562; B1B1 *vs*. B1B2 + B2B2, P = 0.296; B1B1 *vs*. B2B2, P = 0.311).

![Effect size and confidence intervals for studies evaluating *IL-4* rs8179190 and chronic kidney disease susceptibility under dominant model (B1B1 + B1B2 vs. B2B2) using random-effects meta-analysis.](fgene-11-00079-g003){#f3}

The *IL-10* rs1800896 polymorphism was assessed in 6 studies with 2,514 cases and 2,538 controls and was not found to be associated with CKD susceptibility (AA + AG *vs*. GG, OR = 0.99, 95% CI: 0.69--1.42, P = 0.959; AA *vs*. AG + GG, OR = 1.10, 95% CI: 0.81--1.49, P = 0.536; AA *vs*. GG, OR = 1.11, 95% CI: 0.70--1.75, P = 0.665). Stratified analyses did not find any significant association with CKD susceptibility in Caucasians and Asians. Significant heterogeneity was found under all genetic models (I^2^ \> 50%). The results of Egger\'s test suggested that publication bias was unlikely to have been present (AA + AG *vs*. GG, P = 0.490; AA *vs*. AG + GG, P = 0.882; AA *vs*. GG, P = 0.610).

Five studies containing 1,623 cases and 3,733 controls evaluated the *IL-10* rs1800871 polymorphism and its association with susceptibility to CKD ([@B23]; [@B5]; [@B32]; [@B36]; [@B16]). The results of the overall meta-analysis suggested no association of rs1800871 with CKD susceptibility under all genetic models (TT + TC *vs*. CC, OR = 0.82, 95% CI: 0.56--1.20, P = 0.308; TT *vs*. TC + CC, OR = 1.08, 95% CI: 0.93--1.26, P = 0.327; TT *vs*. CC, OR = 0.85, 95% CI: 0.52--1.40, P = 0.523). Stratified analyses by ethnicity did not identify any association in Asians and a Caucasian population. We did not find any evidence of publication bias for this polymorphism (TT + TC *vs*. CC, P = 0.302; TT *vs*. TC + CC, P = 0.282; TT *vs*. CC, P = 0.210).

Sensitivity Analysis {#s3_3}
--------------------

Funnel plots were symmetrical for the studies assessing the *TGF-β1* rs1800470 and rs1800471 polymorphisms ([**Figures 4A, B**](#f4){ref-type="fig"}) For the *TGF-β1* rs1800470 polymorphism, sensitivity analysis showed that removal of the studies by Babel et al., van de Wetering et al., and Cuenca et al. decreased heterogeneity (P~het~ = 0.701, I^2^ = 0%), without significantly influencing the pooled ORs. For *IL-10* rs1800896, removing the studies by Wu et al., Babel et al., and Manchanda et al. abolished between-study heterogeneity (P~het~=0.367, I^2^ = 0.2%) but did not alter the corresponding pooled ORs. For *IL-10* rs1800871, the studies by Manchanda et al. and Okada et al. were the main contributors to heterogeneity.

![Funnel plots for evaluation of publication bias. **(A)** Funnel plot of meta-analysis evaluating rs1800470 and chronic kidney disease susceptibility under dominant model. **(B)** Funnel plot of meta-analysis evaluating rs1800471 and chronic kidney disease susceptibility under dominant model.](fgene-11-00079-g004){#f4}

Discussion {#s4}
==========

CKD is an irreversible and progressive disease with an inverse relationship between inflammation and kidney function. Even early stage CKD displays marked levels of inflammation ([@B34]). Genetic variations of anti-inflammatory cytokines involved in inflammation may be one possible explanation for interindividual differences in susceptibility to CKD. This meta-analysis summarized the evidence to date regarding the relationship between common polymorphisms in the *TGF-β1*, *IL-4*, and *IL-10* genes and CKD susceptibility. The results indicated a significant association of *TGF-β1* rs1800469, *TGF-β1* rs1800470, *TGF-β1*rs1800471, and *IL-4* rs8179190 with CKD susceptibility, while no association was revealed for the *IL-10* rs1800896 and rs1800871 polymorphisms.

TGF-β1 is a multifunctional cytokine with a pronounced immunosuppressive effect, and is also recognized to be involved in renal fibrosis. It functions in both autocrine and paracrine manners to regulate cell proliferation, differentiation, apoptosis, adhesion, immunity, and extracellular matrix (ECM) turnover in the kidney ([@B21]). In CKD cats, urinary TGF-β1 levels (TGF-β1/creatinine ratio) were dramatically up-regulated and could be used as a clinical marker for disease progression ([@B1]). It was showed that impaired renal function and the deterioration in morphology was in part dependent upon the action of TGF-β1 within the kidney in CKD model rats ([@B13]). Previous epidemiological studies implicated three common single nucleotide polymorphisms (SNPs) in the *TGF-β1* gene, namely rs1800469 (C509T), rs1800470 (T869C), and rs1800471 (G915C) in the susceptibility to CKD. In our meta-analysis, there was an association between SNP rs1800469 and CKD susceptibility under dominant and homozygote models (CC + TC *vs*. TT; CC *vs*. TT). Subgroup analysis by ethnicity showed significant results in Asians and Caucasians, respectively. SNP rs1800469 is located in the promoter region of *TGF-β1* that can alter the rate of secretion of TGF-β1 and hence the circulating levels of mature protein. According to the Genotype-Tissue Expression (GTEx) Consortium ([@B10]), this polymorphism is a significant expression quantitative trait loci (eQTL) for *TGF-β1* in spleen and visceral adipose tissue. Grainger and colleagues found that the T allele of SNP rs1800469 was associated with increased circulating TGF-β1 levels in humans ([@B9]). Accumulating evidence suggests that increased levels of TGF-β1 has been linked to the progression of renal disease ([@B22]). This could explain the reduced risk of CKD found in individuals who were homozygous for the C allele or those carrying the C allele when compared to individuals with genotype TT.

For *TGF-β1* rs1800470, an analysis of data from seven studies demonstrated a significant association with CKD susceptibility under all genetic models in Asians but not Caucasians. Frequencies of genetic markers often showed high variations among various ethnic and racial groups, but we found that the median prevalence of the rs1800470 C allele carriers was similar in Asians and Caucasians (66 and 67%). We noticed that this polymorphism was in strong linkage disequilibrium (LD) with *TGF-β1* rs1800469 in Asians including Chinese ([@B39]) and Indians ([@B35]), but not Caucasians ([@B17]). This might be one of the reasons for the ethnic difference. In addition, variation of environmental exposures and gene-environmental interactions among regions, life style factors, patient characteristics, study design, and source of control groups may contribute to the inconsistent results between different racial groups. Concerning *TGF-β1* rs1800471, there was an association with CKD in the overall population and Caucasians. No statistically significant association was observed when data were limited to Asians. However, since there was only one Asian study included in the meta-analysis, more research is necessary to assess this polymorphism among Asians. SNP rs1800471 is a functional variant; it is believed that carriers of the C allele have a higher amount of plasma TGF-β1 ([@B9]). Besides renal fibrosis, SNP rs1800471 has been implicated in the development and progression of several other fibrotic processes, including pulmonary and hepatic fibrosis ([@B25]). Khalil et al. found that among patients with CKD of different origin, there was an association between SNP rs1800471 and rapid progression of CKD ([@B17]). A previous meta-analysis by Mao et al. evaluating the relation of *TGF-β1* polymorphisms with CKD susceptibility reported similar findings for rs1800469 and rs1800470 ([@B24]). However, they did not find any association of rs1800471 with CKD, possibly because they calculated the pooled ORs using a relatively small sample size and applied distinct contrast models.

IL-4 is a pleiotropic cytokine that regulates diverse T and B cell responses. It reduces the production of proinflammatory cytokines and plays a role in renal inflammation. The human IL-4 gene maps to the long arm of chromosome 5 (5q31-33) and contains a variable number of tandem repeat polymorphism (VNTR, rs8179190) located in intron 3 ([@B27]). The functional role of this polymorphism remains largely unknown. Several clinical studies demonstrated that genotype combinations of rs8179190 and other *IL-4* polymorphisms significantly influence IL-4 expression ([@B15]; [@B6]). In addition, rs8179190 was reported to be associated with susceptibility to chronic inflammatory diseases and cancer ([@B3]; [@B28]; [@B46]). We found three studies that assessed the association between *IL-4* rs8179190 and CKD susceptibility. The overall meta-analyses did not show a significant association of this polymorphism with CKD, but stratified analyses indicated an association under dominant model in Asians. To our knowledge, this is the first meta-analysis examining the relationship between *IL-4* rs8179190 and CKD susceptibility.

We found eight studies assessing the association between *IL-10* polymorphisms (rs1800896 and rs1800871) and CKD susceptibility. rs1800896 is an SNP at the --1,082 position in the gene promoter in which guanine (G) replaces the ancestral adenine (A). Studies have shown that G carriers significantly overproduce IL-10 ([@B18]). rs1800871 (--819C/T) is also located in the *IL-10* promoter region which can regulate the levels of circulating IL-10 ([@B32]). Our meta-analysis included several studies containing large sample sizes. The study by Wu et al. recruited 870 cases and 1,000 controls ([@B45]), whereas the study by Okada et al. was conducted in 546 cases and 2,767 controls ([@B32]). Pooling all included studies indicated no association between CKD susceptibility and these *IL-10* polymorphisms. When data were limited to distinct ethnic groups, the results did not make a difference.

Some limitations of the included studies should be acknowledged. First, significant between-study heterogeneity was found in the meta-analyses evaluating rs1800470, rs1800896, and rs1800871. We used sensitivity analysis to identify the studies contributing to heterogeneity and confirmed the stability of the results. Future studies should clearly describe the information on study characteristics, including sex ratio and average age. This may be helpful in exploring precise sources of heterogeneity. Second, although Egger\'s test did not suggest publication bias for studies that analyzed rs1800470, the funnel plot showed some asymmetry. Statistical methods may not successfully detect publication bias when the number of eligible studies is relatively small. Third, in terms of control sources, not all studies recruited healthy individuals as controls. The studies by Cuenca et al. and Kamei et al. recruited patients without CKD after liver transplantation ([@B7]; [@B16]). The study by Prasad et al. included diabetics without any evidence of kidney disease ([@B33]), whereas the study by van de Wetering et al. recruited heart transplant recipients without CKD ([@B40]). The controls from these studies may be at higher risk of developing CKD than the general population, making it more difficult to identify associations of the investigated polymorphisms with CKD development. In addition, in individuals who received organ transplants, immunosuppressant drugs had potential influence on inflammation, confounding the effects of the analyzed polymorphisms on CKD development. Fourth, the included studies were of a case-control design and had a retrospective character. To better elucidate the association between anti-inflammatory cytokine polymorphisms and CKD development, prospective studies based on large sample sizes are needed in the future. Fourth, although our results did not suggest an association of the *IL-10* rs1800896 and rs1800871 polymorphisms with CKD susceptibility, additional functional variants may exist in the *IL-10* gene. There were two studies that assessed other *IL-10* polymorphisms, including rs1800872, rs3024509, rs1554286, rs3024505, rs3021094, and rs1800894 ([@B5]; [@B36]). We were interested in exploring whether there was an association between *IL-10* haplotypes and CKD susceptibility, but this could not be carried out because of limited data. Further studies are needed to address this interesting question.

In summary, this meta-analysis of genetic association studies shows that common polymorphisms in the *TGF-β1* and *IL-4* genes including rs1800469, rs1800470, rs1800471, and rs8179190 may be important genetic contributors to susceptibility to CKD. Future prospective studies based on large sample sizes are needed to further substantiate and enrich the present findings.
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